To the Editor: The study by Dr Simon and colleagues1 appears to provide evidence for the efficacy and
safety of celecoxib, a cyclooxygenase 2 (COX-2) inhibitor. However, several
aspects of their experimental design appear to limit these conclusions.
First, it is most useful to compare a new agent with the most effective
and least toxic existing agent. Although the authors chose naproxen as the
comparison drug, other nonsteroidal anti-inflammatory drugs (NSAIDs), such
as ibuprofen2,3 and nabumetone,4 have less gastrointestinal (GI) tract toxicity.
Also, they began treatment of the comparison group with 500 mg twice per day
of naproxen, which is the maximum suggested initial dosage.5
This is especially troubling because about 40% of this group was older than
60 years and, thus, had a 3-fold risk of NSAID-induced gastropathy.3,6
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.